Higher PD-L1 concordance has been documented in synchronous tumor samples compared with metachronous ones; additionally, a greater clinical benefit with immunotherapy was observed when PD-L1 status was evaluated in metastatic sites [11,45]. The gene discussed is CD274; the disease is neoplasm.